December 4, 2018 Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early this morning focused on a phase III trial using Darzalex (daratumumab) in front-line therapy plus Rev-dex versus Rev-dex only for transplant-ineligible patients. The abstract # LBA-2 showed that the addition of Dara decreased the […]